Sector | Healthcare | Compare with Sector peers |
Industry | Hospital & Healthcare Services | Compare with Industry peers |
Website | http://www.drhlsl.com | |
Market Cap | 22.01 Cr. | |
Enterprise Value(EV) | 24.17 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -0.48 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-03 |
Industry PE | 66.15 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 8.45 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 1.76 | Calculated using Price: 14.86 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 1.48 Cr. | 14,808,706 Shares |
FaceValue | 10 | |
About Samsrita Labs Ltd. | ||
Dr Habeebullah Life Sciences with its group Companies has established platforms in the areas of Stem Cell Research and Therapy, New Drug Discovery, Molecular Prognosis and Diagnostics services, CRO, Stem Cell focused Super Specialty Hospital, RNA Interference Technology and Medical Devices. |
1 Day |
|
+3.92% |
1 Week |
|
-1.29% |
1 Month |
|
-16.89% |
3 Month |
|
-18.94% |
6 Month |
|
-17.34% |
1 Year |
|
-31.82% |
2 Year |
|
-50.61% |
5 Year |
|
-53.60% |
10 Year |
|
7 years | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | -16.62 | -11.85 | -21.62 | -16.88 | -6.71 | 12.29 | -5.48 | |
Return on Capital Employed (%) | -4.07 | -6.81 | -12.27 | -10.1 | -4.53 | 10.2 | -4.61 | |
Return on Assets (%) | -6.9 | -5.06 | -9.63 | -7.4 | -3.47 | 8.89 | -4.32 |
Particulars | 7 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Shh. Funds | 8 | 11 | 12 | 12 | 11 | 13 | 13 | |
Non Curr. Liab. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Curr. Liab. | 7 | 7 | 10 | 12 | 5 | 4 | 3 | |
Minority Int. | 4 | 4 | 4 | 4 | ||||
Equity & Liab. | 19 | 23 | 26 | 28 | 17 | 17 | 16 | |
Non Curr. Assets | 16 | 18 | 20 | 21 | 10 | 10 | 10 | |
Curr. Assets | 3 | 4 | 6 | 7 | 7 | 7 | 6 | |
Misc. Exp. not W/O | ||||||||
Total Assets | 19 | 23 | 26 | 28 | 17 | 17 | 16 |
Particulars | 8 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09 Rs. Cr. TTM | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Net Sales | 1 | 1 | 2 | 1 | 0 | 0 | 0 | ||
Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | |
Total Income | 1 | 1 | 2 | 2 | 0 | 0 | 2 | 0 | |
Total Expenditure | -2 | -2 | -4 | -4 | -1 | 0 | 0 | -1 | |
PBIDT | -1 | -1 | -2 | -2 | -1 | 0 | 2 | -1 | |
Interest | 0 | 0 | |||||||
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Taxation | -1 | 0 | 0 | 0 | 0 | ||||
Exceptional Items | |||||||||
PAT | -1 | -1 | -2 | -2 | -1 | 0 | 2 | -1 | |
Minority Interest | 0 | 0 | 0 | 0 | |||||
Share Associate | 0 | ||||||||
Other Related Items | |||||||||
Consolidated Net Profit | -1 | -1 | -2 | -2 | -1 | 0 | 1 | -1 | |
Adjusted EPS | -1 | -1 | -2 | -1 | -1 | 0 | 1 | 0 |
Particulars | 7 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | -3 | -3 | -1 | 0 | 0 | 1 | |
Cash Fr. Inv. | -1 | -1 | -2 | -1 | 0 | |||
Cash Fr. Finan. | 1 | 5 | 4 | 2 | 1 | 0 | -1 | |
Net Change | 0 | 0 | 0 | 0 | 0 | 0 | ||
Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 |
Wed, 21 Feb 2024
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on February 21 2024 for Krishnam Raju Kalidindi |
Thu, 01 Feb 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication newspaper ad |
Wed, 31 Jan 2024
Results For The Quarter Ended 31.12.2023 Results for the quarter ended 31.12.2023 |
Thu, 28 Mar 2024 |
High Delivery Percentage |
Close Crossing Last Week High |
Closing Above Previous High |
Close Within 52 Week Low Zone |
Close Above Last Week High |